Literature DB >> 8903649

Effect of angiotensinogen on blood pressure regulation in normotensive rats: application of a loss of function approach.

N Tomita1, R Morishita, J Higaki, S Tomita, M Aoki, Y Kaneda, T Ogihara.   

Abstract

OBJECTIVE: To investigate the effect of plasma angiotensinogen on blood pressure regulation in normotensive rats, by a loss of function approach using antisense oligonucleotides. DESIGN AND METHODS: Eight-week-old male Wistar rats were transfected with antisense, sense or scrambled oligonucleotides using liposomes containing viral agglutinins, which are reported to be highly efficient in promoting fusion with target cells. The abdomen was opened with a median incision, and the liver and portal vein were exposed. Then 2.5 ml of hemagglutinating virus-liposome complex containing oligonucleotides was introduced into the liver by multiple direct injections or infusion via the portal vein. Blood pressure, plasma angiotensinogen and angiotensin II levels were measured after transfection. The hepatic angiotensinogen level was examined by Northern blotting and radioimmunoassay.
RESULTS: The in vivo injection of antisense oligonucleotides against rat angiotensinogen by the hemagglutinating virus-liposome gene transfer method into normotensive rats resulted in a transient fall in blood pressure from day 1 to day 4 after injection. This was accompanied by a decrease in plasma angiotensinogen and hepatic angiotensinogen messenger RNA levels on day 2. No significant changes were noted in untreated rats or those treated with sense or scrambled oligonucleotides. Plasma angiotensin II concentration was also reduced by antisense treatment, but not sense or scrambled treatment.
CONCLUSIONS: In vivo administration of antisense angiotensinogen oligonucleotides resulted in a transient decrease in blood pressure accompanied by a decrease in plasma angiotensinogen and angiotensin II levels, which suggests that angiotensinogen plays a pivotal role in the regulation of blood pressure in normotensive rats.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8903649

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  5 in total

Review 1.  Angiotensinogen variants and human hypertension.

Authors:  X Jeunemaitre; A P Gimenez-Roqueplo; J Célérier; P Corvol
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

Review 2.  Transcription factor decoy oligonucleotide-based therapeutic strategy for renal disease.

Authors:  Naruya Tomita; Naoki Kashihara; Ryuichi Morishita
Journal:  Clin Exp Nephrol       Date:  2007-03-28       Impact factor: 2.801

3.  In vivo transfer of antisense oligonucleotide against urinary kininase blunts deoxycorticosterone acetate-salt hypertension in rats.

Authors:  I Hayashi; M Majima; T Fujita; T Okumura; Y Kumagai; N Tomita; R Morishita; J Higaki; T Ogiwara
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

4.  PPARs in the Renal Regulation of Systemic Blood Pressure.

Authors:  Tamás Roszer; Mercedes Ricote
Journal:  PPAR Res       Date:  2010-06-08       Impact factor: 4.964

Review 5.  Antisense oligonucleotides targeting angiotensinogen: insights from animal studies.

Authors:  Chia-Hua Wu; Ya Wang; Murong Ma; Adam E Mullick; Rosanne M Crooke; Mark J Graham; Alan Daugherty; Hong S Lu
Journal:  Biosci Rep       Date:  2019-01-11       Impact factor: 3.976

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.